장기 온칩 시장 : 유형, 재료, 모델 유형, 용도, 최종사용자, 세계 예측(2024-2032년)

The global organs-on-chips market is anticipated to witness more than 32.2% CAGR from 2024 to 2032 driven by the increasing demand for alternatives to animal testing, advancements in technology, and rising investments in R&D.

According to PETA, nearly 76 million procedures are done on animals across the UK. As organizations aim to reduce this number and minimize the dependency on animal testing, the market is anticipated to grow. As organs-on-chips offer a promising platform for mimicking the physiological and mechanical properties of human organs, thus helping in revolutionizing drug development, toxicity testing, and disease modeling.

The organs-on-chips market is classified based on type, material, model type, application, end-user, and region.

The polymer material segment is predicted to record strong CAGR from 2024 to 2032, owing to its versatility, biocompatibility, and tunable properties. Polymers such as polydimethylsiloxane (PDMS) and polyurethane have emerged as popular choices for manufacturing organs-on-chips due to their ability to replicate the microenvironment of human tissues effectively. Moreover, advancements in polymer fabrication techniques, including soft lithography and microfluidics, are further fueling the adoption of polymer-based organs-on-chips platforms across pharmaceutical and biotechnology industries.

The toxicity testing application segment is expected to generate massive revenue by 2032 as they offer a more accurate and predictive alternative to traditional animal testing methods. These microfluidic devices enable researchers to simulate the complex interactions between drugs, chemicals, and human tissues, thereby facilitating early detection of potential toxicity issues and minimizing the reliance on animal models. With regulatory agencies worldwide emphasizing the reduction and replacement of animal testing in drug development, the demand for organs-on-chips for toxicity testing is expected to surge in the coming years.

Europe organs-on-chips market size will expand significantly through 2032 driven by the presence of leading pharmaceutical companies, academic research institutes, and supportive regulatory frameworks. United Kingdom, Germany, and France are significantly investing to accelerate research and commercialization efforts. Additionally, initiatives by regulatory bodies such as the European Medicines Agency (EMA) to promote the adoption of alternative testing methods are fostering the widespread acceptance of organs-on-chips platforms across the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Data validation
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic disease
    • 3.2.1.2 Increasing demand for personalized medicine
    • 3.2.1.3 Growing advancement in organ-on-chip technology
    • 3.2.1.4 Expanding use of organ-on-chip models in biomedical applications
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Challenges and intricacies in implementing organ-on-chip techniques
    • 3.2.2.2 Regulatory obstacles
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Product
  • 5.2.1 Liver-on-chip
  • 5.2.2 Lung-on-chip
  • 5.2.3 Heart-on-chip
  • 5.2.4 Kidney-on-chip
  • 5.2.5 Other products
• 5.3 Service

Chapter 6 Market Estimates and Forecast, By Material, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Polydimethylsiloxane (PDMS)
• 6.3 Polymer
• 6.4 Glass

Chapter 7 Market Estimates and Forecast, By Model Type, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Single-organ model
• 7.3 Multi-organ model

Chapter 8 Organ on Chip Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Drug discovery
• 8.3 Toxicity testing
• 8.4 Disease modeling
• 8.5 Personalized medicine
• 8.6 Other applications

Chapter 9 Market Estimates and Forecast, By End-User, 2018 - 2032 (USD Million)

• 9.1 Key trends
• 9.2 Pharmaceutical and biotechnology companies
• 9.3 Academic and research institutes
• 9.4 Other end-users

Chapter 10 Organ on Chip Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Altis Biosystems
• 11.2 AlveoliX AG
• 11.3 Axosim
• 11.4 Bi/ond Solutions B.V
• 11.5 Cherry Biotech
• 11.6 CN-Bio
• 11.7 Emulate, Inc.
• 11.8 Hesperos, Inc.
• 11.9 Insphero
• 11.10 MesoBioTech
• 11.11 Mimetas B.V.
• 11.12 Nortis Inc.
• 11.13 React4Life
• 11.14 TARA Biosystems (Valo Health)
• 11.15 TissUse GmbH